Results 1 to 10 of about 14,161,615 (319)

X-Ray Determination of the Variable Rate of Mass Accretion onto TW Hydrae [PDF]

ApJ, 760, 2000, L21, 2012
Diagnostics of electron temperature (T_e), electron density (n_e), and hydrogen column density (N_H) from the Chandra High Energy Transmission Grating spectrum of He-like Ne IX in TW Hydrae (TW Hya), in conjunction with a classical accretion model, allow us to infer the accretion rate onto the star directly from measurements of the accreting material ...
Brickhouse, N. S., Cranmer, S. R., Dupree, A. K., Günther, H. M., Luna, G. J. M., Wolk, S. J.   +5 more
arxiv   +5 more sources

Activation of Factor IX by Factor XIa - A Spectrophotometric Assay for Factor IX in Human Plasma [PDF]

Thrombosis and Haemostasis, 1982
SummaryThe activation of Factor IX by partially purified Factor XIa was followed by active site titration, gelelectrophoresis and by a spectrophotometric assay. The assay is based on the finding that the rate of Factor X activation in the presence of phospholipid and Ca2+ is linear in time and proportional to the amount of Factor IXa present and can be
H.C. Hemker, Guido Tans, T. Janssen-Claesssen, G. van Dieijen, Jan Rosing   +4 more
openaire   +6 more sources

Successful immunosuppressive drug‐free immune tolerance induction in hemophilia B with inhibitor and anaphylaxis to factor IX: A case report [PDF]

Clinical Case Reports
Key Clinical Message Recommendations advise factor IX desensitization before immune tolerance induction in severe hemophilia B, supported by immunosuppression.
Ángeles Palomo Bravo, Rosario Prieto Bonilla, Daniel Bardan Rebollar, Francisco José López‐Jaime, Ihosvany Fernández‐Bello   +4 more
doaj   +2 more sources

The Clinical Genetics of Hemophilia B (Factor IX Deficiency) [PDF]

The Application of Clinical Genetics, 2021
Connie H Miller1,2 1Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA; 2Synergy America, Inc., Duluth, GA, USACorrespondence: Connie H MillerDivision
Miller CH
doaj   +2 more sources

Rate-limiting roles of the tenase complex of factors VIII and IX in platelet procoagulant activity and formation of platelet-fibrin thrombi under flow [PDF]

Haematologica, 2015
The importance of factor Xa generation in thrombus formation has not been studied extensively so far. Here, we used mice deficient in either factor VIII or factor IX to determine the role of platelet-stimulated tenase activity in the formation of ...
Frauke Swieringa, Marijke J. E. Kuijpers, Moniek M. E. Lamers, Paola E. J. van der Meijden, Johan W. M. Heemskerk   +4 more
doaj   +5 more sources

Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation.

Proceedings of the National Academy of Sciences of the United States of America, 1977
A study was carried out on mechanisms, independent of activated Factor XI, capable of activating Factor IX. The reaction product of tissue factor and Factor VII functioned as a potent Factor IX activator in the assay system used.
B Osterud, S I Rapaport
openalex   +2 more sources

Enhanced Factor IX Activity following Administration of AAV5-R338L “Padua” Factor IX versus AAV5 WT Human Factor IX in NHPs [PDF]

Molecular Therapy: Methods & Clinical Development, 2019
Gene therapy for severe hemophilia B is advancing and offers sustained disease amelioration with a single treatment. We have reported the efficacy and safety of AMT-060, an investigational gene therapy comprising an adeno-associated virus serotype 5 ...
Elisabeth A. Spronck, Ying Poi Liu, Jacek Lubelski, Erich Ehlert, Sander Gielen, Paula Montenegro-Miranda, Martin de Haan, Bart Nijmeijer, Valerie Ferreira, Harald Petry, Sander J. van Deventer   +10 more
doaj   +5 more sources

Factor IX p.A37V mutation causes severe bleeding in a patient with phenprocoumon therapy [PDF]

European Journal of Medical Research, 2021
Background Bleeding is the most common complication of oral anticoagulants, due to inadequate dosing. Case presentation This report describes the clinical course of a patient who developed severe bleeding under therapy with phenprocoumon, despite an INR ...
Nils Mülling, Vivian Rosery, H. Christian Reinhardt, Maher Hanoun   +3 more
doaj   +2 more sources

A Post-Authorization Safety Surveillance Study to Report Clinical Experience with Purified Factor IX Concentrate in Pediatric Patients with Hemophilia B [PDF]

Journal of Blood Medicine
Zoran Igrutinović,1,2 Hélène Louise Hooimeijer,3 Karim Kentouche,4 Jaco Botha,5 Peter L Turecek,6 Marta Kokot-Kierepa,5 Hanna T Gazda7 1Clinic of Pediatrics, Department of Hemato-Oncology, University Clinical Center of Kragujevac, Kragujevac ...
Igrutinović Z, Hooimeijer HL, Kentouche K, Botha J, Turecek PL, Kokot-Kierepa M, Gazda HT   +6 more
doaj   +2 more sources

Encapsulation of factor IX–engineered mesenchymal stem cells in fibrinogen–alginate microcapsules enhances their viability and transgene secretion

Journal of Tissue Engineering, 2012
Cell microencapsulation holds significant promise as a strategy for cellular therapies; however, inadequate survival and functionality of the enclosed cells limit its application in hemophilia treatment.
Bahareh Sayyar, Megan Dodd, Jianping Wen, Shirley Ma, Leah Marquez-Curtis, Anna Janowska-Wieczorek, Gonzalo Hortelano   +6 more
doaj   +2 more sources